Blog of the MHRA on Transfer of Analytical Methods
Recommendation

Thursday, 3 September 2026 9 .00 - 17.00 h
Establishment, Use and Maintenance of Analytical Reference Substances
The regulatory authority of the United Kingdom, the MHRA (Medicines and Healthcare products Regulatory Agency), regularly provides information on GMP-relevant topics in a blog on its website.
In August 2021, the topic "transfer of analytical methods" was addressed here and the GMP requirements listed. In this blog edition the tasks of the transferring parties are exemplified and explained.
Frequent Findings
Likewise, a list of frequently occurring deficiencies and sources of error can be found in this post. According to the MHRA, the following points are among the most frequent findings in the subject area "transfer of analytical methods":
- Equipment not qualified for the transferring method
- The transfer protocol is not followed
- The transfer is performed for only one strength of product, although the method is used for additional strengths
- Methods reference documents from the transferring party, which are not available in the receiving laboratory
- The GAP analyses are not complete
- The method transfer was only performed on one batch with one test of each of the different methods (assays/dissolution, etc.)
To get more details please see the MHRA Inspeectorate Blog "transfer of analytical methods".
Related GMP News
01.07.2026Several FDA Warning Letters and Untitled Letters on Asbestos Testing of Talc in OTC Drug Products
24.06.2026Analytical Quality Group Developments January through April 2026
17.06.2026BioPhorum Publishes a Roadmap for QC Sample Test Execution
03.06.2026EMA Provides an Outlook on the Product-Specific Bioequivalence Guidelines Expected in 2026
03.06.2026FDA Warning Letter: Missing Method Validation - From a QC Topic to a Market-Access Problem
28.05.2026WHO Working Document on Bioequivalence open for Public Consultation


